Abstract
During and after 233 cycles of cis-diamminedichloroplatinum (II) (CDDP), 197 serial audiograms were obtained in 48 patients and compared with baseline audiograms. Use was made of three dose schedules (20 mg/m2, 25-50 mg/m2 and 70-120 mg/m2), two regimens (single-day or daily for 5 days) and three modes of administration (rapid infusion, 2- or 3-hr infusion, 24-hr infusion). Clinical hearing loss occurred in 12.5% and tinnitus in 25% of all patients. The incidence of audiographic changes (65% overall, 81% bilaterally) increased with increasing cumulative CDDP dose independent of treatment schedule. The incidence was correlated with the daily dose (P = 0.0037) and changes were more severe after single high doses. No difference was found between the single low dose and the daily for 5 days regimen. Rapid infusion of a single high dose was more ototoxic than a 24-hr infusion of the same dose (P = 0.0015). It is concluded that, compared with the single high-dose regimen, the daily low dose for 5 days is preferable in cases where the patient might be cured by a regimen including CDDP.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 53-58 |
| Number of pages | 6 |
| Journal | European Journal of Cancer and Clinical Oncology |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1983 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Ototoxicity of cis-diamminedichloroplatinum (II) : Influence of dose, schedule and mode of administration. / Vermorken, J. B.; Kapteijn, T. S.; Hart, A. A M; Pinedo, H. M.
In: European Journal of Cancer and Clinical Oncology, Vol. 19, No. 1, 1983, p. 53-58.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ototoxicity of cis-diamminedichloroplatinum (II)
T2 - Influence of dose, schedule and mode of administration
AU - Vermorken, J. B.
AU - Kapteijn, T. S.
AU - Hart, A. A M
AU - Pinedo, H. M.
PY - 1983
Y1 - 1983
N2 - During and after 233 cycles of cis-diamminedichloroplatinum (II) (CDDP), 197 serial audiograms were obtained in 48 patients and compared with baseline audiograms. Use was made of three dose schedules (20 mg/m2, 25-50 mg/m2 and 70-120 mg/m2), two regimens (single-day or daily for 5 days) and three modes of administration (rapid infusion, 2- or 3-hr infusion, 24-hr infusion). Clinical hearing loss occurred in 12.5% and tinnitus in 25% of all patients. The incidence of audiographic changes (65% overall, 81% bilaterally) increased with increasing cumulative CDDP dose independent of treatment schedule. The incidence was correlated with the daily dose (P = 0.0037) and changes were more severe after single high doses. No difference was found between the single low dose and the daily for 5 days regimen. Rapid infusion of a single high dose was more ototoxic than a 24-hr infusion of the same dose (P = 0.0015). It is concluded that, compared with the single high-dose regimen, the daily low dose for 5 days is preferable in cases where the patient might be cured by a regimen including CDDP.
AB - During and after 233 cycles of cis-diamminedichloroplatinum (II) (CDDP), 197 serial audiograms were obtained in 48 patients and compared with baseline audiograms. Use was made of three dose schedules (20 mg/m2, 25-50 mg/m2 and 70-120 mg/m2), two regimens (single-day or daily for 5 days) and three modes of administration (rapid infusion, 2- or 3-hr infusion, 24-hr infusion). Clinical hearing loss occurred in 12.5% and tinnitus in 25% of all patients. The incidence of audiographic changes (65% overall, 81% bilaterally) increased with increasing cumulative CDDP dose independent of treatment schedule. The incidence was correlated with the daily dose (P = 0.0037) and changes were more severe after single high doses. No difference was found between the single low dose and the daily for 5 days regimen. Rapid infusion of a single high dose was more ototoxic than a 24-hr infusion of the same dose (P = 0.0015). It is concluded that, compared with the single high-dose regimen, the daily low dose for 5 days is preferable in cases where the patient might be cured by a regimen including CDDP.
UR - http://www.scopus.com/inward/record.url?scp=0020659723&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020659723&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(83)90398-X
DO - 10.1016/0277-5379(83)90398-X
M3 - Article
VL - 19
SP - 53
EP - 58
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
SN - 0277-5379
IS - 1
ER -